ACADIA Pharmaceuticals' GAAP loss for the 3 months of 2022 was $113.056 million, up 70.1% from $66.448 million in the previous year. Revenue increased 8.4% to $115.468 million from $106.554 million a year earlier.

ACADIA Pharmaceuticals' GAAP loss for 2021 was $167.87 million, down 40.4% from $281.584 million in the previous year. Revenue increased 9.6% to $484.145 million from $441.755 million a year earlier.

ACADIA Pharmaceuticals reported a GAAP loss of $124.776 million for 9M 2021, down 41.9% from $214.824 million in the previous year. Revenue increased 10.2% to $353.387 million from $320.748 million a year earlier.

ACADIA Pharmaceuticals reported a GAAP loss of $110.319 million for the six months of 2021, down 15.2% from $130.164 million in the previous year. Revenue increased 10.8% to $221.775 million from $200.171 million a year earlier.